Bone and bone marrow interactions: Hematological activity of osteoblastic growth peptide (OGP)-derived carboxy-terminal pentapeptide: III. Action on human megakaryocytopoiesis: Focus on essential thrombocythemia

Leukemia Research

Volumn 28, Issue 10, 2004, Pages 1097-1105

  Fazzi, Rita ^a   Galimberti, Sara ^a   Pacini, Simone ^a   Testi, Rossana ^a   Azzarà, Antonio ^a   Orciuolo, Enrico ^a   Trombi, Luisa ^a   Metelli, Maria Rita ^a   Petrini, Mario ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

CFU Mk; Essential thrombocythemia; Megakaryocytopoiesis; OGP10 14; TGF 1

Indexed keywords

GROWTH FACTOR; HISTORPHIN; OSTEOGENIC GROWTH PEPTIDE; SYNTHETIC PEPTIDE; THROMBOPOIETIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL PROLIFERATION; CLINICAL ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; HUMAN; HUMAN CELL; MEGAKARYOBLAST; MEGAKARYOCYTE; MEGAKARYOPOIESIS; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; THROMBOCYTHEMIA;

BONE MARROW; CELL PROLIFERATION; CYTOKINES; ENDORPHINS; HISTONES; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MEGAKARYOCYTES; OSTEOBLASTS; PLATELET-DERIVED GROWTH FACTOR; STRUCTURE-ACTIVITY RELATIONSHIP; THROMBOCYTHEMIA, HEMORRHAGIC; TRANSFORMING GROWTH FACTOR BETA1;

EID: 3843099308     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2004.01.019     Document Type: Article

References (29)

1. Harrison C.N., Gale R.E., Machin S.J., et al. A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications. Blood. 93:1999;417-424
2. Li Y., Hetet G., Maurer A.M., et al. Spontaneous megakaryocyte colony formation in myeloproliferative disorders is not neutralizable by antibodies against IL3, IL6 and GM-CSF. Br. J. Haematol. 87:1994;471-476
3. Li Y., Hetet G., Kiladjian J.J., et al. Proto-oncogene c-mpl is involved in spontaneous megakaryocytopoiesis in myeloproliferative disorders. Br. J. Haematol. 92:1996;60-66
4. Taksin A.L., Couedic J.P., Dusanter-Fourt I., et al. Autonomous megakaryocyte growth in essential thrombocythemia and idiopathic myelofibrosis is not related to a c-mpl mutation or to an autocrine stimulation by Mpl-L. Blood. 93:1999;125-139
5. Li J., Xia Y., Kuter D.J. The platelet thrombopoietin receptor number and function are markedly decreased in patients with essential thrombocythaemia. Br. J. Haematol. 111:2000;943-953
6. Westwood N.B., Pearson T.C. Diagnostic applications of haemopoietic progenitor culture techniques in polycythaemias and thrombocythaemias. Leuk. Lymphoma. 22(Suppl. 1):1996;95-103
7. Zweegman S., Veenhof M.A., Huijgens P.C., et al. Regulation of megakaryocytopoiesis in an in vitro stroma model: preferential adhesion of megakaryocytic progenitors and subsequent inhibition of maturation. Exp. Hematol. 28:2000;401-410
8. Gurevitch O., Slavin S., Muhlrad A., et al. Osteogenic growth peptide increases blood and bone marrow cellularity and enhances engraftment of bone marrow transplants in mice. Blood. 88:1996;4719-4724
9. Fazzi R., Testi R., Trasciatti S., et al. Bone and bone-marrow interactions: haematological activity of osteoblastic growth peptide (OGP)-derived carboxy-terminal pentapeptide. Mobilizing properties on white blood cells and peripheral blood stem cells in mice. Leuk. Res. 26:2002;19-27
10. Fazzi R., Galimberti S., Testi R., et al. Bone and bone marrow interactions: hematological activity of osteoblastic growth peptide (OGP)-derived carboxy-terminal pentapeptide. II. Action on human hematopoietic stem cells. Leuk. Res. 26:2002;839-848
11. Fazzi R., Pacini S., Testi R., et al. Carboxy-terminal fragment of osteogenic growth peptide in vitro increases bone marrow cell density in idiopathic myelofibrosis. Br. J. Haematol. 121:2003;76-85
12. Chen Y.C., Bab I., Mansur N., et al. Structure-bioactivity of C-terminal pentapeptide of osteogenic growth peptide [OGP(10-14)]. J. Pept. Res. 56:2000;147-156
13. Murphy S., Iland H., Rosenthal D., Laszlo J. Essential thrombocythemia: an interim report from the Polycythemia Vera Study Group. Semin. Hematol. 23:1986;177
14. Hogge D., Fanning S., Bockhold K., et al. Quantitation and characterization of human megakaryocyte colony-forming cells using a standardized serum-free agarose assay. Br. J. Haematol. 96:1997;790-800
15. Petrini M., Caracciolo F., Carulli G., et al. Vitamin D3 administration and multidrug resistance in acute nonlymphoblastic leukemia. Acta Haematol. 89:1993;184-188
16. Drexler H.G., Quentmeier H. Cytokine response profiles of human myeloid factor-dependent leukemia cell lines. Leukemia. 11:1997;701-708
17. Testi R., Mattii L., Di Simone D., et al. Evaluation of resistance index of several anticancer agents on parental and resistant P-388 cell lines. Leuk. Res. 19:1995;257-261
18. Junker U., Haufe C.C., Nuske K., et al. Elevated plasma TGF-beta1 in renal diseases: cause or consequence? Cytokine. 12:2000;1084-1091
19. Hart C.E., Bailey M., Curtis D.A., et al. Purification of PDGF-AB and PDGF-BB from human platelet extracts and identification of all three PDGF dimers in human platelets. Biochemistry. 29:1990;166-172
20. Bailly S., Fay M., Ferrua B., et al. Comparative production of IL-1 beta and IL-1 alpha by LPS-stimulated human monocytes: ELISAs measurement revisited. Cytokine. 6:1994;111-115
21. Aukrust P., Liabakk N.B., Muller F., et al. Serum levels of tumor necrosis factor-alpha (TNF alpha) and soluble TNF receptors in human immunodeficiency virus type 1 infection - correlations to clinical, immunologic, and virologic parameters. J. Infect. Dis. 169:1994;420-424
22. Di Simone D., Testi R., Caracciolo F., et al. Glutathione-S-transferase activity and multidrug resistance phenotype in chronic lymphocytic leukemia: do they have any clinical relevance? Haematologica. 80:1995;103-107
23. Bab I., Gazit D., Muhlrad A., et al. Regenerating bone marrow produces a potent growth-promoting activity to osteogenic cells. Endocrinology. 123:1988;345-352
24. Bab I., Gazit D., Chorev M., et al. Histone H4-related osteogenic growth peptide (OGP): a novel circulating stimulator of osteoblastic activity. EMBO J. 11:1992;1867-1873
25. Bab I., Gavish H., Namdar-Attar M., et al. Isolation of mitogenically active C-terminal truncated pentapeptide of osteogenic growth peptide from human plasma and culture medium of murine osteoblastic cells. J. Pept. Res. 54:1999;408-414
26. Axelrad A.A., Eskinazi D., Correa P.N., et al. Hypersensitivity of circulating progenitor cells to megakaryocyte growth and development factor (PEG-rHu MGDF) in essential thrombocythemia. Blood. 96:2000;3310-3321
27. Fortunel N.O., Hatzfeld A J.A. Transforming growth factor-beta: pleiotropic role in the regulation of hematopoiesis. Blood. 96:2000;2022-2036
28. Kalina U., Koschmieder S., Hofmann W.K., et al. Transforming growth factor-beta1 interferes with thrombopoietin-induced signal transduction in megakaryoblastic and erythroleukemic cells. Exp. Hematol. 29:2001;602-608
29. Sakamaki S., Hirayama Y., Matsunaga T., et al. Transforming growth factor-beta1 (TGF-beta1) induces thrombopoietin from bone marrow stromal cells, which stimulates the expression of TGF-beta receptor on megakaryocytes and, in turn, renders them susceptible to suppression by TGF-beta itself with high specificity. Blood. 94:1999;1961-1970